Compare Ascendis Pharma A/S (ASND) vs The Vita Coco Company Inc (COCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs The Vita Coco Company Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while The Vita Coco Company Inc trades at $71.23 (market cap $4.08B). The key difference: Ascendis Pharma A/S is far larger — about 4.3× The Vita Coco Company Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, The Vita Coco Company Inc nearer its low. Which is the better fit depends on your goals.
| ASND | COCO | |
|---|---|---|
Market Cap | $17.74B | $4.08B |
Sector | Health | Technology |
52-Week High | $277.18 | $84.02 |
52-Week Low | $163.32 | $32.30 |
Enterprise Value | $18.11B | $3.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Vita Coco (COCO) trades at $71.40, up 0.21% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with 37.4% gross margins and 26.32% ROE, though valuation metrics appear elevated with a P/E of 51.74. Recent Q1 2026 earnings beat expectations by 47%, while analysts maintain a 60% buy rating consensus with a $78 price target. The company is scheduled to report Q2 2026 results on July 23, 2026.
COCO presents growth potential driven by market leadership in coconut water and projected revenue expansion to $659M in 2026. However, premium valuation and competitive pressures in the beverage sector warrant caution. The stock's near-term catalyst will be Q2 earnings performance against the $0.56 EPS expectation, with technical support at $69 and resistance at $73.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →
